Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  RegeneRx Biopharmaceuticals, ... announced that an independent team of researchers from ... that Thymosin B4 (TB4) plays an important role ... wounds, induced in an experimental mouse model, by ... remodeling of damaged dermal tissue.  The research found ...
(Date:5/4/2015)... - New Massive Open Online ... for the United States Medical Licensing Examination ... and medical information products and services, announced today that ... Course) designed to help medical students prepare for the ... first and most daunting of the three exams medical ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... 8 Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: ... of a putative securities class action lawsuit, In re ... The Company has agreed to pay in settlement US$1 ... The settlement must be approved by the Court. ...
... AcelRx Pharmaceuticals, Inc.,announced today it has hired Dr. ... this new position, Dr. Skowronski will be responsible ... medical input,and review of clinical development strategy. ... Chief Medical Officer. , ...
... CHICAGO, Jan. 8 Allscripts announced today that,Tully-Wihr ... signed a,definitive agreement to resell the web-based Allscripts ... to 100 physicians. , ... Founded in 1906, Tully-Wihr has been building ...
Cached Biology Technology:Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 2Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 3Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 4Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians 5
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... , April 2, 2015 ... touch fingerprint sensor FPC1025 from the distributor World Peace ... commence during Q2 2015 although the major part of ... sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... in space create in humans and animals so-called optical flow ... a forward movement, the objects flow by laterally, objects at ... change at all. At a higher level in the visual ... the visual information, so that animals can differentiate between their ...
... major differences between women with serious depression and healthy ... and emotions. , The study adds further evidence ... the brain -- specifically in the endogenous opioid system ... pain and stress-reduction system. The findings also show significant ...
... Professor Nigel Dimmock at the University of Warwick is ... This has been shown to protect animals against ... the full range of influenza A infections, including H5N1 ... The 'protecting virus' provides instant protection, and completely prevents ...
Cached Biology News:Two nerve cells in direct contact 2Two nerve cells in direct contact 3New brain-chemistry differences found in depressed women 2New brain-chemistry differences found in depressed women 3'Protecting virus' offers instant flu protection and converts flu infections into their own vaccines 2'Protecting virus' offers instant flu protection and converts flu infections into their own vaccines 3
...
...
... and supplies, for 10 chips, provides ... perform high-sensitivity RNA analysis (picogram levels) ... automated electrophoresis system. Supplied are 1,250 ... HighSens stain, 20 microliters RNA ladder, ...
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
Biology Products: